One of the main challenges in oncology is the development of drugs against KRAS oncogenes. These oncogenes -genes that cause cancer when mutated - are responsible for a quarter of all human cancers, including the three tumor types with the highest mortality rates: lung adenocarcinoma, colorectal carcinoma and pancreatic ductal adenocarcinoma.